Cross-Sector entity
All 2 tracked stories fall under one category: earnings. Legence is most often covered alongside Acacia Research, which appears in 2 of these 2 stories. The tracked stories average 3 original sources each. Legence appears in 2 tracked Cross-Sector stories from August 14, 2026.
2 verified stories tracked
Last mentioned: Aug 14, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: earnings. Legence is most often covered alongside Acacia Research, which appears in 2 of these 2 stories. The tracked stories average 3 original sources each. Legence appears in 2 tracked Cross-Sector stories from August 14, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Legence. Shared-story counts are live from our verified record — not editorial picks.
MP Materials and Maravai Q2 2026 transcripts released
Call transcripts were published for the rare-earth and life-science companies.
Acacia Research Q2 2026 Earnings Call
Record $114.6M revenue from IP licensing settlement; Life Sciences write-down disclosed.
Datadog's Q2 2026 call, led by CEO Olivier Pomel and CFO David Obstler, focused on product capabilities and cloud market opportunities. The cluster also includes Acacia's $114.6M IP settlement, highlighting software-adjacent IP monetization.
Q2 2026 earnings show Acacia Research's record $114.6M IP-settlement revenue countered by a Life Sciences write-down, while Dutch Bros grew 32.5%. Datadog, MP Materials, and Maravai add cloud, rare-earth, and biotech signals for investors.
Source: Yahoo! News · Fool
